HEOR Publications
HEOR resources
BeiGene is committed to developing transparent, actionable clinical and health economic information.
The publications below have been presented at international meetings and congresses, including AMCP, ISPOR, ASH, ASCO, and ESMO.
These publications may contain information about unapproved uses of or indications for products or investigational drugs that have not received FDA approval in the United States.
Click the VIEW MORE button below to access additional publications.
Recurrent Patient-Reported Outcome-Based Symptomatic Deterioration Predicts Progression-Free Survival: Results From RATIONALE-305
Presented at:
European Society for Medical Oncology (ESMO); September 13-17, 2024; Barcelona, Spain
View
Comparative Efficacy and Safety of Tislelizumab Versus Anti-PD-1 Treatments in Second Line Esophageal Squamous Cell Carcinoma: Simulated Treatment Comparisons
Presented at:
European Society for Medical Oncology (ESMO); September 13-17, 2024; Barcelona, Spain
View
Tislelizumab Plus Chemotherapy vs Placebo Plus Chemo as First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Health-Related Quality of Life Outcomes in the RATIONALE-305 Study
Presented at:
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI); January 18-20, 2024; San Francisco, CA
View
Zanubrutinib Versus Acalabrutinib in B-cell Malignancies: An Adverse Event-Based Economic Analysis
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
View more
Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
Efficacy and Safety of Zanubrutinib Versus Venetoclax+Ibrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
Matching-Adjusted Indirect Comparison of Zanubrutinib Versus Real-World Chemoimmunotherapy or Chemotherapy in Relapsed/Refractory Marginal Zone Lymphoma
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
Patient-Reported Outcome (PRO)-Based Recurrent Symptomatic Deterioration Predicts Disease Progression: Results From the ALPINE Trial
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
Real-World Bruton Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in US Community Oncology Practices
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
Real-World Adherence and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
Real-World Comparative Effectiveness of Covalent Bruton Tyrosine Inhibitors Among Patients With Relapsed/Refractory Mantle Cell Lymphoma
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
Real-World Evaluation of Treatment Pattern, Time to Next Treatment, Healthcare Resource Utilization, and Cost of Care in Follicular Lymphoma
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
Real-World Treatment Switching and Sequencing to Next Line of Therapy of Zanubrutinib, Acalabrutinib, and Ibrutinib in CLL/SLL
Presented at:
European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain
View
Clinical and Financial Burden of Mental Health Conditions in Patients With Low-Grade Non-Hodgkin Lymphoma
Presented at:
ASCO Annual Meeting; May 31-June 4, 2024; Chicago, IL
View
Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis
Presented at:
ASCO Annual Meeting; May 31-June 4, 2024; Chicago, IL
View
Real-World Treatment Patterns and Outcomes of Zanubrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (CLL/SLL)
Presented at:
ASCO Annual Meeting; May 31-June 4, 2024; Chicago, IL
View
Budget Impact Analysis of Zanubrutinib + Obinutuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma in the United States
Presented at:
ISPOR Annual Meeting; May 5-8, 2024; Atlanta, GA
View
Targeted Literature Review of Cost-Effectiveness Models in Relapsed/Refractory Follicular Lymphoma
Presented at:
ISPOR Annual Meeting; May 5-8, 2024; Atlanta, GA
View
Zanubrutinib vs FCR in Treatment-Naïve Patients With Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
Presented at:
British Society for Haematology (BSH) Annual Scientific Meeting; April 28-30, 2024; Liverpool, England
View
Similar Ibrutinib Efficacy Across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: Matching-Adjusted Indirect Comparison
Presented at:
AMCP Annual Meeting; April 15-18, 2024; New Orleans, LA
View
Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL): A Matching-Adjusted Indirect Comparison (MAIC)
Presented at:
ICHM Annual Meeting; February 29-March 3, 2024; Miami Beach, FL
View
Impact of Real-World Treatment Sequencing Patterns on Time to Next Treatment Among Patients With Chronic Lymphocytic Leukemia in the United States
Presented at:
ASH Annual Meeting; December 9-12, 2023; San Diego, CA
View
Number Needed to Treat Analysis of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia
Presented at:
ASH Annual Meeting; December 9-12, 2023; San Diego, CA
View
Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients With Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices
Presented at:
ASH Annual Meeting; December 9-12, 2023; San Diego, CA
View
Real-World Patterns of Care and Financial Burden of Patients With Follicular Lymphoma in the United States
Presented at:
ASH Annual Meeting; December 9-12, 2023; San Diego, CA
View
Real-World Evaluation of Treatment Discontinuation and Healthcare Resource Utilization in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Presented at:
ASH Annual Meeting; December 9-12, 2023; San Diego, CA
View
Recent Patterns of Care With BTK Inhibitors and Distribution of Social Determinants of Health Among Patients With CLL/SLL in the US Community Setting
Presented at:
ASH Annual Meeting; December 9-12, 2023; San Diego, CA
View
Real-World Switching Patterns, Persistence, and Associated Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States
Presented at:
ASH Annual Meeting; December 9-12, 2023; San Diego, CA
View
Global Clinical, Economic, Health-Related Quality of Life Burden and Treatment Outcomes in Follicular Lymphoma: A Systematic Review
Presented at:
ISPOR EU 2023 Annual Meeting; November 12-15, 2023; Copenhagen, Denmark
View
Cost Minimization Analysis of Bruton Tyrosine Kinase Inhibitors in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia
Presented at:
ISPOR EU 2023 Annual Meeting; November 12-15, 2023; Copenhagen, Denmark
View
Unmet Needs and Evidence Gaps in Relapsed/Refractory Marginal Zone Lymphoma: Findings From a Systematic Literature Review
Presented at:
ISPOR EU 2023 Annual Meeting; November 12-15, 2023; Copenhagen, Denmark
View
Targeted Treatments for Patients With Relapsed and/or Refractory (R/R) Chronic Lymphocytic Leukemia: A Systematic Literature Review of Randomized Clinical Trials
Presented at:
ISPOR EU 2023 Annual Meeting; November 12-15, 2023; Copenhagen, Denmark
View
Open Insurance Claims Database vs Closed Insurance Claims Database to Support Pharmacovigilance Review of Potential Safety Events in Patients With B-Cell Malignancies: A Fit-for-Purpose Evaluation
Presented at:
The ICPE 2023 Annual Conference; August 23-27, 2023; Halifax, NS, Canada
View
Literature Review of Statistical Methods Comparisons Through Simulations When Using External Control Arm for Regulatory or HTA Submissions
Presented at:
ISPOR 2023; May 7-10, 2023; Boston, MA
View
Real World Evidence of Impact of Atrial Fibrillation on Clinical and Economic Outcomes in Patients With Chronic Lymphocytic Leukemia
Presented at:
The Hematology/Oncology Pharmacy Association (HOPA) Annual Conference; March 29-April 1, 2023; Phoenix, AZ
View
Budget Impact Analysis of Zanubrutinib for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the United States
Presented at:
ISPOR EU 2022 Annual Meeting; November 6-9, 2022; Vienna, Austria
View
Lessons Learned From Successful Real-World Evidence (RWE) Studies Supporting Regulatory Drug Approvals
Presented at:
ISPOR EU 2022 Annual Meeting; November 6-9, 2022; Virtual
View